Michael Untch Selected Research

Breast Neoplasms (Breast Cancer)

2/2022	Update Breast Cancer 2021 Part 4 - Prevention and Early Stages.
2/2022	ABC6 Consensus: Assessment by a Group of German Experts.
1/2022	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial.
1/2022	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
1/2022	Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
1/2022	Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
1/2022	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
12/2021	How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer.
10/2021	Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
10/2021	AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Untch Research Topics

Disease

205	Breast Neoplasms (Breast Cancer) 02/2022 - 07/2002
71	Neoplasms (Cancer) 10/2022 - 01/2003
26	Triple Negative Breast Neoplasms 10/2022 - 06/2014
25	Pathologic Complete Response 11/2021 - 06/2009
7	Neoplasm Metastasis (Metastasis) 10/2021 - 01/2010
6	Disease Progression 01/2020 - 01/2003
6	Infections 01/2020 - 06/2004
6	Neutropenia 01/2020 - 06/2004
4	Vomiting 01/2020 - 07/2002
4	Febrile Neutropenia 01/2020 - 06/2004
4	Nausea 01/2020 - 07/2002
4	Exanthema (Rash) 01/2016 - 02/2012
4	Cardiotoxicity 03/2013 - 06/2003
3	Brain Neoplasms (Brain Tumor) 02/2022 - 03/2018
3	Residual Neoplasm 01/2019 - 02/2009
3	Carcinoma (Carcinomatosis) 10/2017 - 01/2003
3	Diarrhea 07/2015 - 04/2010
3	Thrombocytopenia (Thrombopenia) 06/2014 - 06/2009
3	Anemia 07/2009 - 02/2008
2	Amenorrhea 01/2021 - 01/2019
2	Breast Diseases (Breast Disease) 06/2020 - 01/2020
2	Inflammatory Breast Neoplasms 11/2019 - 10/2014
2	Circulating Neoplastic Cells 09/2017 - 05/2010
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 07/2014
2	Heart Failure 03/2016 - 03/2010
2	Lobular Carcinoma 02/2014 - 06/2013
2	Hand-Foot Syndrome 01/2012 - 04/2010

Drug/Important Bio-Agent (IBA)

49	Trastuzumab (Herceptin)FDA Link 12/2021 - 06/2003
40	Hormones (Hormone)IBA 01/2022 - 07/2002
29	taxaneIBA 10/2021 - 08/2004
25	human ERBB2 proteinIBA 01/2021 - 04/2010
24	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 01/2003
24	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 07/2002
24	AnthracyclinesIBA 01/2021 - 02/2008
23	Epirubicin (Ellence)FDA LinkGeneric 10/2022 - 08/2004
17	Lapatinib (GW572016)FDA Link 01/2021 - 02/2006
12	ErbB Receptors (EGF Receptor)IBA 12/2021 - 03/2010
11	Estrogen ReceptorsIBA 10/2021 - 07/2002
10	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 06/2014
10	Phenobarbital (Luminal)FDA Link 01/2022 - 10/2011
10	Bevacizumab (Avastin)FDA Link 01/2020 - 01/2010
9	Capecitabine (Xeloda)FDA Link 01/2022 - 10/2004
9	Docetaxel (Taxotere)FDA Link 01/2020 - 04/2010
8	Biomarkers (Surrogate Marker)IBA 05/2021 - 10/2011
6	130-nm albumin-bound paclitaxelIBA 01/2022 - 04/2012
6	pertuzumabIBA 06/2021 - 03/2013
6	Pharmaceutical PreparationsIBA 02/2021 - 05/2006
5	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 06/2003
5	Tamoxifen FDA LinkGeneric 01/2020 - 02/2007
5	Biological ProductsIBA 01/2020 - 02/2006
5	Monoclonal AntibodiesIBA 01/2017 - 10/2005
4	liposomal doxorubicin (Doxil)FDA Link 01/2022 - 01/2017
4	Immunoconjugates (Immunoconjugate)IBA 05/2021 - 01/2019
4	Immune Checkpoint InhibitorsIBA 05/2021 - 10/2016
4	Messenger RNA (mRNA)IBA 01/2021 - 02/2013
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 02/2022 - 01/2018
3	Tyrosine Kinase InhibitorsIBA 12/2021 - 01/2009
3	PlatinumIBA 11/2021 - 01/2003
3	Ado-Trastuzumab EmtansineIBA 10/2020 - 01/2019
3	MicroRNAs (MicroRNA)IBA 02/2020 - 08/2014
3	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 07/2002
3	Cytotoxins (Cytolysins)IBA 01/2019 - 10/2004
3	Epidermal Growth Factor (EGF)IBA 11/2017 - 02/2014
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2015 - 03/2004
3	Aromatase InhibitorsIBA 04/2013 - 02/2007
3	Taxoids (Taxanes)IBA 04/2012 - 01/2011
3	epoetin betaIBA 11/2009 - 02/2008
2	pembrolizumabIBA 10/2022 - 01/2020
2	neratinibIBA 12/2021 - 06/2021
2	veliparibIBA 11/2021 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 10/2017
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2020 - 01/2018
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 06/2004
2	SolventsIBA 01/2019 - 03/2016
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2016
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 11/2017 - 10/2014
2	Indicators and Reagents (Reagents)IBA 04/2017 - 01/2017
2	Formaldehyde (Formol)FDA Link 10/2016 - 10/2014
2	ParaffinIBA 10/2016 - 10/2014
2	N,N'-bis(4-azidobenzoyl)cystineIBA 02/2016 - 02/2014
2	exemestane (Aromasin)FDA Link 01/2016 - 12/2008
2	AntibodiesIBA 03/2013 - 01/2009
2	Erythropoietin FDA Link 07/2009 - 02/2008
2	HematinicsIBA 07/2009 - 05/2009
2	Phosphotransferases (Kinase)IBA 01/2009 - 02/2006
2	Estrogens (Estrogen)FDA Link 11/2008 - 06/2007
2	Acetates (Acetic Acid Esters)FDA Link 06/2007 - 07/2002
2	Leuprolide (Lupron)FDA LinkGeneric 06/2007 - 07/2002

Therapy/Procedure

90	Neoadjuvant Therapy 10/2022 - 04/2006
87	Therapeutics 10/2022 - 01/2003
65	Drug Therapy (Chemotherapy) 10/2022 - 07/2002
15	Adjuvant Chemotherapy 01/2022 - 10/2005
6	Radiotherapy 10/2021 - 07/2014
4	Precision Medicine 06/2020 - 03/2018
4	Mastectomy (Mammectomy) 11/2019 - 08/2015
4	Aftercare (After-Treatment) 11/2018 - 10/2011
4	Segmental Mastectomy (Lumpectomy) 10/2017 - 10/2014
3	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 10/2004
2	Operative Surgical Procedures 10/2021 - 02/2005
2	Erythrocyte Transfusion 07/2009 - 05/2009